The Vector Labs are structured and organized under a new paradigm for Vector Core operations that is designed to provide investigators with a single source that can supply their vector needs throughout the development of the research programs. The labs utilize an integrated systems approach to speed the flow of vector technologies and information. These systems are designed to provide comprehensive resources to investigators so they can avoid many of the common pitfalls and delays that occur during the translational research period. These pitfalls and delays are caused when a specific vector-disease approach must transition from a basic research environment into the highly regulated and controlled processes of final preclinical safety testing and human clinical trials. The UNC Vector Labs will support MTCC investigators by providing expertise with vector design, construction, and development as well as by providing investigators with the viral vector reagents themselves. Investigators will be able to select the optimal type of viral platform (adenoviral, AAV, lentiviral, retroviral, PIV, cell-based, or plasmid) for the specific research in which they are involved. Investigators can also select from a range of standard quality grades (research, preclinical, or clinical), or can custom design intermediate grades as necessary. The combined staff at the Vector Labs and the Gene Therapy Center have prior experience in bringing to clinical trials virtually all the major viral platforms. Investigators will be able to utilize this experience to aid in creating drug development templates as their research progresses into the clinical arena.

Public Health Relevance

The Vector Core will provide a broad range of services that will benefit public health. Its foremost mission is to provide gene transfer vectors that will treat people with genetic diseases. An important parallel mission is to develop gene transfer vectors that may aid in immunization of the general population to a variety of communicable diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
3P30DK065988-10S1
Application #
8851228
Study Section
Special Emphasis Panel (ZDK1-GRB-1)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
10
Fiscal Year
2014
Total Cost
$68,400
Indirect Cost
$23,400
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Sesma, Juliana I; Weitzer, Clarissa D; Livraghi-Butrico, Alessandra et al. (2016) UDP-glucose promotes neutrophil recruitment in the lung. Purinergic Signal 12:627-635
Mitchel, Jennifer A; Antoniak, Silvio; Lee, Joo-Hyeon et al. (2016) IL-13 Augments Compressive Stress-Induced Tissue Factor Expression in Human Airway Epithelial Cells. Am J Respir Cell Mol Biol 54:524-31
Livraghi-Butrico, A; Grubb, B R; Wilkinson, K J et al. (2016) Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. Mucosal Immunol :
Button, Brian; Anderson, Wayne H; Boucher, Richard C (2016) Mucus Hyperconcentration as a Unifying Aspect of the Chronic Bronchitic Phenotype. Ann Am Thorac Soc 13 Suppl 2:S156-62
Cholon, Deborah M; Esther Jr, Charles R; Gentzsch, Martina (2016) Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Expert Rev Precis Med Drug Dev 1:235-243
Yu, Dongfang; Davis, Richard M; Aita, Megumi et al. (2016) Characterization of Rat Meibomian Gland Ion and Fluid Transport. Invest Ophthalmol Vis Sci 57:2328-43
Dang, Hong; Gallins, Paul J; Pace, Rhonda G et al. (2016) Novel variation at chr11p13 associated with cystic fibrosis lung disease severity. Hum Genome Var 3:16020
Menachery, Vineet D; Yount Jr, Boyd L; Sims, Amy C et al. (2016) SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A 113:3048-53
Watson, Michael J; Lee, Shernita L; Marklew, Abigail J et al. (2016) The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Uses its C-Terminus to Regulate the A2B Adenosine Receptor. Sci Rep 6:27390
Blackmon, Richard L; Kreda, Silvia M; Sears, Patrick R et al. (2016) Diffusion-sensitive optical coherence tomography for real-time monitoring of mucus thinning treatments. Proc SPIE Int Soc Opt Eng 9697:

Showing the most recent 10 out of 92 publications